Showing 501-510 of 3494 results for "".
- FDA Accepts Galderma’s RelabotulinumtoxinA BLA Resubmissionhttps://practicaldermatology.com/news/fda-accepts-galdermas-relabotulinumtoxina-bla-resubmission/2485601/Galderma announced that the US Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess™) for the temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines in a
- Analysis: ChatGPT and DeepSeek Largely Align With Psoriasis Treatment Guidelineshttps://practicaldermatology.com/news/analysis-chatgpt-and-deepseek-largely-align-with-psoriasis-treatment-guidelines/2485578/Large language models (LLMs) ChatGPT and DeepSeek generally adhere to established psoriasis treatment guidelines, but some performance gaps remain. Investigators publishing in the Journal of Drugs in Dermatology exp
- AbbVie Files FDA, EMA Applications for Upadacitinib in Non-Segmental Vitiligohttps://practicaldermatology.com/news/abbvie-files-fda-ema-applications-for-upadacitinib-in-non-segmental-vitiligo/2485564/AbbVie has submitted regulatory applications to the US Food and Drug Administration and European Medicines Agency seeking approval of upadacitinib (RINVOQ) for the treatment of adults and adolescents with non-segmental vitiligo (NSV), according to a
- 23-Gene Expression Profiling Accurately Classifies Pediatric Melanocytic Lesionshttps://practicaldermatology.com/news/23-gene-expression-profiling-accurately-classifies-pediatric-melanocytic-lesions/2485549/A 23-gene expression profiling assay accurately distinguished benign nevi from melanoma in pediatric patients, according to “23-GEP Accurately Distinguishes Between Melanocytic Nevi and Melanoma in Pediatric Melanocytic Neoplasms,” a poster by Drazen Jukic, MD, et al presented as part of the “Bes
- FDA Approves Once-Daily Oral Semaglutidehttps://practicaldermatology.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- MEK Inhibition Shows Promise in Aggressive EB-Linked Skin Cancershttps://practicaldermatology.com/news/mek-inhibition-shows-promise-in-aggressive-eb-linked-skin-cancers/2485197/A transcriptome-driven drug repurposing strategy has identified selumetinib as a potential therapeutic candidate for aggressive squamous cell carcinomas (SCCs) arising in recessive dystrophic epidermolysis bullosa (RDEB). Resea
- FDA: Most PFAS in Cosmetics Lack Adequate Safety Datahttps://practicaldermatology.com/news/fda-most-pfas-in-cosmetics-lack-adequate-safety-data/2485144/The U.S. Food and Drug Administration (FDA) announced that it has released its first congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), assessing the use and safety of perfluoroalkyl and polyfluoroalkyl substances (PF
- Contact Dermatitis, Unlabeled Ingredients Among Concerns in Self-Tannershttps://practicaldermatology.com/news/contact-dermatitis-unlabeled-ingredients-among-concerns-in-self-tanners/2485034/A recent review in the Journal of Drugs in Dermatology raised some concerns regarding ingredient safety and adverse reactions. Researchers on the study analyzed the top 50 best-selling sunless tanning products on Amazon
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://practicaldermatology.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to
- FDA Takes First Step Toward Expanding Sunscreen Optionshttps://practicaldermatology.com/news/fda-takes-first-step-toward-expanding-sunscreen-options/2484881/The American Academy of Dermatology Association (AADA) released a statement from organization president Susan C. Taylor, MD, FAAD commending the Food and Drug Administration (FDA) for taking its first significant step in more than 20 years toward expanding safe and